Ignite Creation Date:
2025-12-25 @ 12:40 AM
Ignite Modification Date:
2026-01-24 @ 11:38 PM
Study NCT ID:
NCT02279667
Status:
COMPLETED
Last Update Posted:
2015-01-01
First Post:
2014-10-29
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D004827', 'term': 'Epilepsy'}], 'ancestors': [{'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C416835', 'term': 'eslicarbazepine acetate'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'jose.rocha@bial.com', 'phone': '+351 229 866 100', 'title': 'Head of Clinical Research', 'organization': 'Bial - Portela & Cª, S.A.'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'BIA 2-093 16 mL Oral Suspension 50 mg/mL', 'description': 'BIA 2-093, ESL, Eslicarbazepine acetate oral suspension 50 mg/mL', 'otherNumAtRisk': 18, 'otherNumAffected': 3, 'seriousNumAtRisk': 18, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'BIA 2-093 - Four 200 mg Tablets', 'description': 'BIA 2-093, ESL, Eslicarbazepine acetate 200 mg tablets', 'otherNumAtRisk': 18, 'otherNumAffected': 1, 'seriousNumAtRisk': 18, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'BIA 2-093 One 800 mg Tablet', 'description': 'BIA 2-093, ESL, Eslicarbazepine acetate 800 mg tablet', 'otherNumAtRisk': 18, 'otherNumAffected': 0, 'seriousNumAtRisk': 18, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Follow-up', 'description': 'Follow-up.', 'otherNumAtRisk': 18, 'otherNumAffected': 1, 'seriousNumAtRisk': 18, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Blepharitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (4.1)'}, {'term': 'CPK increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 18, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (4.1)'}, {'term': 'Drowsiness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 18, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (4.1)'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (4.1)'}, {'term': 'Migraine type headaches', 'stats': [{'groupId': 'EG000', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (4.1)'}, {'term': 'Localized erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (4.1)'}, {'term': 'Facial flushing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 18, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (4.1)'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Cmax - the Maximum Plasma Concentration', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'BIA 2-093 16 mL Oral Suspension 50 mg/mL', 'description': 'BIA 2-093 (ESL, Eslicarbazepine acetate) 16 mL oral suspension 50 mg/mL'}, {'id': 'OG001', 'title': 'BIA 2-093 - Four 200 mg Tablets', 'description': 'BIA 2-093 (ESL, Eslicarbazepine acetate) - Four 200 mg tablets'}, {'id': 'OG002', 'title': 'BIA 2-093 One 800 mg Tablet', 'description': 'BIA 2-093 (ESL, Eslicarbazepine acetate) - One 800 mg tablet'}], 'classes': [{'categories': [{'measurements': [{'value': '18048', 'spread': '4644', 'groupId': 'OG000'}, {'value': '16007', 'spread': '4008', 'groupId': 'OG001'}, {'value': '17042', 'spread': '4131', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose', 'description': 'Cmax - the maximum plasma concentration of BIA 2-093 metabolite: BIA 2-005', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Tmax - the Time of Occurrence of Cmax', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'BIA 2-093 16 mL Oral Suspension 50 mg/mL', 'description': 'BIA 2-093 (ESL, Eslicarbazepine acetate) 16 mL oral suspension 50 mg/mL'}, {'id': 'OG001', 'title': 'BIA 2-093 - Four 200 mg Tablets', 'description': 'BIA 2-093 (ESL, Eslicarbazepine acetate) - Four 200 mg tablets'}, {'id': 'OG002', 'title': 'BIA 2-093 One 800 mg Tablet', 'description': 'BIA 2-093 (ESL, Eslicarbazepine acetate) - One 800 mg tablet'}], 'classes': [{'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000', 'lowerLimit': '1', 'upperLimit': '4'}, {'value': '3', 'groupId': 'OG001', 'lowerLimit': '1.5', 'upperLimit': '6'}, {'value': '3', 'groupId': 'OG002', 'lowerLimit': '1', 'upperLimit': '4'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose', 'description': 'Tmax - the Time of Occurrence of maximum plasma concentration of BIA 2-093 metabolite: BIA 2-005', 'unitOfMeasure': 'hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'BIA 2-093 16 mL Oral Suspension 50 mg/mL', 'description': 'BIA 2-093 (ESL, Eslicarbazepine acetate) 16 mL oral suspension 50 mg/mL'}, {'id': 'OG001', 'title': 'BIA 2-093 - Four 200 mg Tablets', 'description': 'BIA 2-093 (ESL, Eslicarbazepine acetate) - Four 200 mg tablets'}, {'id': 'OG002', 'title': 'BIA 2-093 One 800 mg Tablet', 'description': 'BIA 2-093 (ESL, Eslicarbazepine acetate) - One 800 mg tablet'}], 'classes': [{'categories': [{'measurements': [{'value': '323277', 'spread': '64055', 'groupId': 'OG000'}, {'value': '302026', 'spread': '65270', 'groupId': 'OG001'}, {'value': '299016', 'spread': '58806', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose', 'description': 'AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time of BIA 2-093 metabolite: BIA 2-005', 'unitOfMeasure': 'ng*h/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'BIA 2-093 16 mL Oral Suspension 50 mg/mL', 'description': 'BIA 2-093 (ESL, Eslicarbazepine acetate) 16 mL oral suspension 50 mg/mL'}, {'id': 'OG001', 'title': 'BIA 2-093 - Four 200 mg Tablets', 'description': 'BIA 2-093 (ESL, Eslicarbazepine acetate) - Four 200 mg tablets'}, {'id': 'OG002', 'title': 'BIA 2-093 One 800 mg Tablet', 'description': 'BIA 2-093 (ESL, Eslicarbazepine acetate) - One 800 mg tablet'}], 'classes': [{'categories': [{'measurements': [{'value': '325732', 'spread': '64898', 'groupId': 'OG000'}, {'value': '304219', 'spread': '66045', 'groupId': 'OG001'}, {'value': '301065', 'spread': '59957', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose', 'description': 'AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity of BIA 2-093 metabolite: BIA 2-005', 'unitOfMeasure': 'ng*h/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Group A', 'description': '1. st period - 16 mL oral suspension 50 mg/mL\n2. nd period - Four 200 mg tablets\n3. rd period - One 800 mg tablet'}, {'id': 'FG001', 'title': 'Group B', 'description': '1. st period - One 800 mg tablet\n2. nd period - 16 mL oral suspension 50 mg/mL\n3. rd period - Four 200 mg tablets'}, {'id': 'FG002', 'title': 'Group C', 'description': '1. st period - Four 200 mg tablets\n2. nd period - One 800 mg tablet\n3. rd period - 16 mL oral suspension 50 mg/mL'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '6'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '6'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '18', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'Group A', 'description': '1. st period - 16 mL oral suspension 50 mg/mL\n2. nd period - Four 200 mg tablets\n3. rd period - One 800 mg tablet'}, {'id': 'BG001', 'title': 'Group B', 'description': '1. st period - One 800 mg tablet\n2. nd period - 16 mL oral suspension 50 mg/mL\n3. rd period - Four 200 mg tablets'}, {'id': 'BG002', 'title': 'Group C', 'description': '1. st period - Four 200 mg tablets\n2. nd period - One 800 mg tablet\n3. rd period - 16 mL oral suspension 50 mg/mL'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '18', 'groupId': 'BG003'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 18}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2004-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-12', 'completionDateStruct': {'date': '2004-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-12-31', 'studyFirstSubmitDate': '2014-10-29', 'resultsFirstSubmitDate': '2014-11-28', 'studyFirstSubmitQcDate': '2014-10-29', 'lastUpdatePostDateStruct': {'date': '2015-01-01', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2014-12-31', 'studyFirstPostDateStruct': {'date': '2014-10-31', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2015-01-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2004-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Cmax - the Maximum Plasma Concentration', 'timeFrame': 'Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose', 'description': 'Cmax - the maximum plasma concentration of BIA 2-093 metabolite: BIA 2-005'}, {'measure': 'Tmax - the Time of Occurrence of Cmax', 'timeFrame': 'Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose', 'description': 'Tmax - the Time of Occurrence of maximum plasma concentration of BIA 2-093 metabolite: BIA 2-005'}, {'measure': 'AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time', 'timeFrame': 'Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose', 'description': 'AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time of BIA 2-093 metabolite: BIA 2-005'}, {'measure': 'AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity', 'timeFrame': 'Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose', 'description': 'AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity of BIA 2-093 metabolite: BIA 2-005'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Epilepsy']}, 'descriptionModule': {'briefSummary': 'Single centre, open-label, randomised, three-way crossover study in 18 healthy subjects (9 males and 9 females). The study consisted of three consecutive single-dose treatment periods separated by a washout period of 7 days or more. On each treatment period, the volunteers received a single dose of BIA 2-093 800 mg, orally.', 'detailedDescription': 'Sample size (planned and analyzed): It was planned to have at least 16 healthy subjects completed and evaluable. Taking into account the potential occurrence of dropouts, two additional subjects were to be recruited and entered the study. Therefore, a total of 18 subjects were enrolled.\n\nDiagnosis and main selection criteria: Healthy male or female volunteers aged between 18 and 45 years, with body mass index between 19 and 28 kg/m2, non-smokers or smoking less than 10 cigarettes or equivalent per day.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Male or female subjects aged between 18 and 45 years, inclusive.\n* Subjects of body mass index (BMI) between 19 and 28 kg/m2, inclusive.\n* Subjects who were healthy as determined by pre-study medical history, physical examination, vital signs and 12-lead ECG at screening.\n* Subjects who had clinical laboratory tests clinically acceptable at screening.\n* Subjects who were negative for HBsAg, anti-HCV Ab and HIV-1 and HIV-2 Ab tests at screening.\n* Subjects who were negative for alcohol and drugs of abuse at screening.\n* Subjects who were non-smokers or who smoke less than 10 cigarettes or equivalent per day.\n* Subjects who were able and willing to give written informed consent.\n* (If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: doublebarrier, intra-uterine device or abstinence.\n* (If female) She had a negative pregnancy test at screening and admission to each study period.\n\nExclusion Criteria:\n\n* Subjects who do not conform to the above inclusion criteria, or\n* Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders.\n* Subjects who have a clinically relevant surgical history.\n* Subjects who have a clinically relevant family history.\n* Subjects who have a history of relevant atopy.\n* Subjects who have a history of any drug hypersensitivity.\n* Subjects who have a history of alcoholism or drug abuse.\n* Subjects who consume more than 14 units of alcohol a week.\n* Subjects who have a significant infection or known inflammatory process on screening and/or first admission.\n* Subjects who have acute gastrointestinal symptoms at the time of screening and/or first admission (e.g., nausea, vomiting, diarrhoea, heartburn).\n* Subjects who have used medicines within 2 weeks of admission to first period.\n* Subjects who have participated in any clinical trial within 3 months prior to screening.\n* Subjects who have previously received BIA 2-093.\n* Subjects who have donated and/or received any blood or blood products within the previous 3 months prior to screening.\n* Subjects who are vegetarians, vegans and/or have medical dietary restrictions.\n* Subjects who cannot communicate reliably with the investigation team.\n* Subjects who are unlikely to co-operate with the requirements of the study.\n* Subjects who are unwilling or unable to give written informed consent.\n* (If female) She is pregnant or breast-feeding.\n* (If female) She is of childbearing potential and she does not use an approved effective contraceptive method or she uses oral contraceptives.'}, 'identificationModule': {'nctId': 'NCT02279667', 'briefTitle': 'Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093', 'organization': {'class': 'INDUSTRY', 'fullName': 'Bial - Portela C S.A.'}, 'officialTitle': 'Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093 in Healthy Volunteers', 'orgStudyIdInfo': {'id': 'BIA-2093-109'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Group A', 'description': '1. st period - 16 mL oral suspension 50 mg/mL\n2. nd period - Four 200 mg tablets\n3. rd period - One 800 mg tablet', 'interventionNames': ['Drug: BIA 2-093']}, {'type': 'EXPERIMENTAL', 'label': 'Group B', 'description': '1. st period - One 800 mg tablet\n2. nd period - 16 mL oral suspension 50 mg/mL\n3. rd period - Four 200 mg tablets', 'interventionNames': ['Drug: BIA 2-093']}, {'type': 'EXPERIMENTAL', 'label': 'Group C', 'description': '1. st period - Four 200 mg tablets\n2. nd period - One 800 mg tablet\n3. rd period - 16 mL oral suspension 50 mg/mL', 'interventionNames': ['Drug: BIA 2-093']}], 'interventions': [{'name': 'BIA 2-093', 'type': 'DRUG', 'otherNames': ['ESL, Eslicarbazepine acetate'], 'description': 'oral suspension 50 mg/mL', 'armGroupLabels': ['Group A', 'Group B', 'Group C']}, {'name': 'BIA 2-093', 'type': 'DRUG', 'otherNames': ['ESL, Eslicarbazepine acetate'], 'description': '200 mg tablet', 'armGroupLabels': ['Group A', 'Group B', 'Group C']}, {'name': 'BIA 2-093', 'type': 'DRUG', 'otherNames': ['ESL, Eslicarbazepine acetate'], 'description': '800 mg tablet', 'armGroupLabels': ['Group A', 'Group B', 'Group C']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Azinhaga de Santa Comba - Celas', 'state': 'Coimbra District', 'country': 'Portugal', 'facility': 'CEB - Centre for Bioavailability Studies, AIBILI'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Bial - Portela C S.A.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}